CAMBRIDGE, Mass., Aug. 25, 2022 -- Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced...
TargeGen closes on $40 million venture round
News | 07. 12. 2007
TargeGen
TargeGen, Inc. has announced that the Company has successfully closed a $40M venture round of financing.
